Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Nyxoah ( (NYXH) ).
On September 18, 2025, Nyxoah SA announced the entry into an underwriting agreement for a public offering of ordinary shares, with Morgan Stanley, Stifel, and Cantor Fitzgerald as underwriters. The offering, expected to close around September 23, 2025, aims to raise funds for the commercialization of the Genio system in the U.S. and other markets, support clinical research, and finance R&D activities. This strategic move is expected to bolster Nyxoah’s market positioning and operational capabilities, potentially impacting stakeholders positively by extending the company’s cash runway into late 2026 or 2027.
The most recent analyst rating on (NYXH) stock is a Buy with a EUR14.50 price target. To see the full list of analyst forecasts on Nyxoah stock, see the NYXH Stock Forecast page.
More about Nyxoah
Nyxoah is a medical technology company focused on developing and commercializing innovative solutions for treating Obstructive Sleep Apnea (OSA). Their primary product, the Genio system, offers a patient-centered, leadless, and battery-free hypoglossal neurostimulation therapy for OSA, a common sleep disorder associated with increased mortality risk and cardiovascular comorbidities.
Average Trading Volume: 68,921
Current Market Cap: €160.6M
Find detailed analytics on NYXH stock on TipRanks’ Stock Analysis page.